Sachetta’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sachetta’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03K	Buy	+18	New	+$986	﹤0.01%	885
2025 Q2	–	Sell	-62	Closed	-$4.38K	–	1112
2025 Q1	$4.38K	Buy	62 +8	+15%	+$538	﹤0.01%	590
2024 Q4	$3.55K	Buy	54 +39	+260%	+$2.61K	﹤0.01%	686
2024 Q3	$1.05K	Sell	15 -7	-32%	-$585	﹤0.01%	1022
2024 Q2	$1.86K	Sell	22 -1	-4%	-$83	﹤0.01%	853
2024 Q1	$2.22K	Hold	23	–	–	﹤0.01%	705
2023 Q4	$2.22K	Buy	+23	New	+$2.04K	﹤0.01%	705

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SAM

Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sachetta's BMRN Position: Q2 2026 in Review

Sachetta opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 18 shares worth $1.03K. The stake represents ﹤0.01% of the portfolio and ranks #885 among its holdings. This is a return to the name: Sachetta previously reported a position in BMRN as recently as Q1 2025.

Sachetta first reported a position in BMRN in Q4 2023 and has held it in 7 quarters since. The position peaked at $4.38K in Q1 2025. 74 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Sachetta held 18 shares of BioMarin Pharmaceuticals worth $1.03K as of Q2 2026.
BioMarin Pharmaceuticals was a new Sachetta position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Sachetta's portfolio in Q2 2026, its #885 holding.
Sachetta first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
Sachetta's BioMarin Pharmaceuticals position peaked at $4.38K in Q1 2025.
74 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.